124 related articles for article (PubMed ID: 31637714)
1. SMARCD1 is a transcriptional target of specific non-hotspot mutant p53 forms.
Adduri RSR; George SA; Kavadipula P; Bashyam MD
J Cell Physiol; 2020 May; 235(5):4559-4570. PubMed ID: 31637714
[TBL] [Abstract][Full Text] [Related]
2. COTI-2, A Novel Thiosemicarbazone Derivative, Exhibits Antitumor Activity in HNSCC through p53-dependent and -independent Mechanisms.
Lindemann A; Patel AA; Silver NL; Tang L; Liu Z; Wang L; Tanaka N; Rao X; Takahashi H; Maduka NK; Zhao M; Chen TC; Liu W; Gao M; Wang J; Frank SJ; Hittelman WN; Mills GB; Myers JN; Osman AA
Clin Cancer Res; 2019 Sep; 25(18):5650-5662. PubMed ID: 31308060
[TBL] [Abstract][Full Text] [Related]
3. Disruption of TP63-miR-27a* Feedback Loop by Mutant TP53 in Head and Neck Cancer.
Chari NS; Ivan C; Le X; Li J; Mijiti A; Patel AA; Osman AA; Peterson CB; Williams MD; Pickering CR; Caulin C; Myers JN; Calin GA; Lai SY
J Natl Cancer Inst; 2020 Mar; 112(3):266-277. PubMed ID: 31124563
[TBL] [Abstract][Full Text] [Related]
4. Novel oncogenic transcriptional targets of mutant p53 in esophageal squamous cell carcinoma.
George SA; Kotapalli V; Ramaswamy P; Kumar R; Gowrishankar S; Uppin SG; Bashyam MD
J Cell Biochem; 2024 Apr; 125(4):e30534. PubMed ID: 38358025
[TBL] [Abstract][Full Text] [Related]
5. Long Non-coding MIR205HG Depletes Hsa-miR-590-3p Leading to Unrestrained Proliferation in Head and Neck Squamous Cell Carcinoma.
Di Agostino S; Valenti F; Sacconi A; Fontemaggi G; Pallocca M; Pulito C; Ganci F; Muti P; Strano S; Blandino G
Theranostics; 2018; 8(7):1850-1868. PubMed ID: 29556360
[TBL] [Abstract][Full Text] [Related]
6. Gain-of-function mutant p53 promotes the oncogenic potential of head and neck squamous cell carcinoma cells by targeting the transcription factors FOXO3a and FOXM1.
Tanaka N; Zhao M; Tang L; Patel AA; Xi Q; Van HT; Takahashi H; Osman AA; Zhang J; Wang J; Myers JN; Zhou G
Oncogene; 2018 Mar; 37(10):1279-1292. PubMed ID: 29269868
[TBL] [Abstract][Full Text] [Related]
7. Functionally impactful TP53 mutations are associated with increased risk of extranodal extension in clinically advanced oral squamous cell carcinoma.
Gleber-Netto FO; Neskey D; Costa AFM; Kataria P; Rao X; Wang J; Kowalski LP; Pickering CR; Dias-Neto E; Myers JN
Cancer; 2020 Oct; 126(20):4498-4510. PubMed ID: 32797678
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-7 Compromises p53 Protein-dependent Apoptosis by Controlling the Expression of the Chromatin Remodeling Factor SMARCD1.
Hong CF; Lin SY; Chou YT; Wu CW
J Biol Chem; 2016 Jan; 291(4):1877-1889. PubMed ID: 26542803
[TBL] [Abstract][Full Text] [Related]
9. Mutant p53 in head and neck squamous cell carcinoma: Molecular mechanism of gain‑of‑function and targeting therapy (Review).
Li M; Sun D; Song N; Chen X; Zhang X; Zheng W; Yu Y; Han C
Oncol Rep; 2023 Sep; 50(3):. PubMed ID: 37449494
[TBL] [Abstract][Full Text] [Related]
10. p53-targeted lincRNA-p21 acts as a tumor suppressor by inhibiting JAK2/STAT3 signaling pathways in head and neck squamous cell carcinoma.
Jin S; Yang X; Li J; Yang W; Ma H; Zhang Z
Mol Cancer; 2019 Mar; 18(1):38. PubMed ID: 30857539
[TBL] [Abstract][Full Text] [Related]
11. Dominant-negative p53 mutant R248Q increases the motile and invasive activities of oral squamous cell carcinoma cells.
Nakazawa S; Sakata KI; Liang S; Yoshikawa K; Iizasa H; Tada M; Hamada JI; Kashiwazaki H; Kitagawa Y; Yamazaki Y
Biomed Res; 2019; 40(1):37-49. PubMed ID: 30787262
[TBL] [Abstract][Full Text] [Related]
12. The cancer-associated, gain-of-function TP53 variant P152Lp53 activates multiple signaling pathways implicated in tumorigenesis.
Singh S; Kumar M; Kumar S; Sen S; Upadhyay P; Bhattacharjee S; M N; Tomar VS; Roy S; Dutt A; Kundu TK
J Biol Chem; 2019 Sep; 294(38):14081-14095. PubMed ID: 31366730
[TBL] [Abstract][Full Text] [Related]
13. Transcriptional Regulation by Wild-Type and Cancer-Related Mutant Forms of p53.
Pfister NT; Prives C
Cold Spring Harb Perspect Med; 2017 Feb; 7(2):. PubMed ID: 27836911
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of p53 dysregulations in feline oral squamous cell carcinoma and non-neoplastic oral mucosa.
Renzi A; De Bonis P; Morandi L; Lenzi J; Tinto D; Rigillo A; Bettini G; Bellei E; Sabattini S
PLoS One; 2019; 14(4):e0215621. PubMed ID: 30998743
[TBL] [Abstract][Full Text] [Related]
15. MiR-34a inhibits the proliferation, migration, and invasion of oral squamous cell carcinoma by directly targeting SATB2.
Ge X; Gao J; Sun QW; Wang CX; Deng W; Mao GY; Li HQ; Guo SS; Cheng J; Wu YN; Ye JH
J Cell Physiol; 2020 May; 235(5):4856-4864. PubMed ID: 31663131
[TBL] [Abstract][Full Text] [Related]
16. Expression of SESN1, UHRF1BP1, and miR-377-3p as prognostic markers in mutated TP53 squamous cell carcinoma of the head and neck.
El Baroudi M; Machiels JP; Schmitz S
Cancer Biol Ther; 2017 Oct; 18(10):775-782. PubMed ID: 28886272
[TBL] [Abstract][Full Text] [Related]
17. FOXA1-induced LINC01207 facilitates head and neck squamous cell carcinoma via up-regulation of TNRC6B.
Chen C; Jiang L; Zhang Y; Zheng W
Biomed Pharmacother; 2020 Aug; 128():110220. PubMed ID: 32450521
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-504 functions as a tumor suppressor in oral squamous cell carcinoma through inhibiting cell proliferation, migration and invasion by targeting CDK6.
Wang X; Chang K; Gao J; Wei J; Xu G; Xiao L; Song G
Int J Biochem Cell Biol; 2020 Feb; 119():105663. PubMed ID: 31812760
[TBL] [Abstract][Full Text] [Related]
19. Stathmin is overexpressed and regulated by mutant p53 in oral squamous cell carcinoma.
Ma HL; Jin SF; Ju WT; Fu Y; Tu YY; Wang LZ; Jiang-Li ; Zhang ZY; Zhong LP
J Exp Clin Cancer Res; 2017 Aug; 36(1):109. PubMed ID: 28806997
[TBL] [Abstract][Full Text] [Related]
20. iRhom2 in the pathogenesis of oral squamous cell carcinoma.
Agwae ME; Shaw RJ; Triantafyllou A; Greaney FST; Ben Salah K; Risk JM
Mol Biol Rep; 2020 May; 47(5):3987-3992. PubMed ID: 32236893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
